

# Patrick Micke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7760432/publications.pdf>

Version: 2024-02-01

108  
papers

8,896  
citations

87723

38  
h-index

48187

88  
g-index

112  
all docs

112  
docs citations

112  
times ranked

16746  
citing authors

#	ARTICLE	IF	CITATIONS
1	Difficulties in diagnostics of lung tumours in biopsies: an interpathologist concordance study evaluating the international diagnostic guidelines. <i>Journal of Clinical Pathology</i> , 2022, 75, 302-309.	1.0	7
2	Spatial Immunology in Liver Metastases from Colorectal Carcinoma according to the Histologic Growth Pattern. <i>Cancers</i> , 2022, 14, 689.	1.7	7
3	Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. <i>European Journal of Cancer</i> , 2022, 168, 128-137.	1.3	6
4	Highly elevated systemic inflammation is a strong independent predictor of early mortality in advanced non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100556.	0.7	3
5	Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 873532.	1.3	3
6	Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. <i>Cell Death and Differentiation</i> , 2021, 28, 1477-1492.	5.0	26
7	Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function. <i>Cancer Research</i> , 2021, 81, 956-967.	0.4	104
8	Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 151, 53-59.	0.9	17
9	PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2577-2587.	2.0	14
10	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. <i>EBioMedicine</i> , 2021, 65, 103269.	2.7	25
11	Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation. <i>Lung Cancer</i> , 2021, 155, 10-19.	0.9	28
12	Targeting hepatocyte growth factor in epithelial-stromal interactions in an in vitro experimental model of human periodontitis. <i>Odontology / the Society of the Nippon Dental University</i> , 2021, 109, 912-920.	0.9	3
13	High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC. <i>Cancers</i> , 2021, 13, 3151.	1.7	2
14	Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade. <i>Cancers</i> , 2021, 13, 3116.	1.7	17
15	FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. <i>European Journal of Cancer</i> , 2021, 151, 136-149.	1.3	20
16	Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer. <i>Journal of Pathology</i> , 2021, 255, 243-256.	2.1	17
17	The Immune Landscape of Colorectal Cancer. <i>Cancers</i> , 2021, 13, 5545.	1.7	14
18	TGF- $\beta$ 2-mediated epithelial-mesenchymal transition and tumor-promoting effects in CMT64 cells are reflected in the transcriptomic signature of human lung adenocarcinoma. <i>Scientific Reports</i> , 2021, 11, 22380.	1.6	5

#	ARTICLE	IF	CITATIONS
19	An integrative proteomics method identifies a regulator of translation during stem cell maintenance and differentiation. <i>Nature Communications</i> , 2021, 12, 6558.	5.8	16
20	Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 2456.	1.5	10
21	Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1075-1085.	1.2	38
22	Programmed Cell Death Ligand 1 Expression in Resected Nonâ€“Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 22, e555-e562.	1.1	1
23	The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model. <i>Frontiers in Oncology</i> , 2020, 10, 1717.	1.3	4
24	The protein expression profile of ACE2 in human tissues. <i>Molecular Systems Biology</i> , 2020, 16, e9610.	3.2	769
25	Topographical Distribution and Spatial Interactions of Innate and Semi-Innate Immune Cells in Pancreatic and Other Periapillary Adenocarcinoma. <i>Frontiers in Immunology</i> , 2020, 11, 558169.	2.2	18
26	Comprehensive analysis of RNA binding motif protein 3 (RBM3) in nonâ€“small cell lung cancer. <i>Cancer Medicine</i> , 2020, 9, 5609-5619.	1.3	10
27	Platelet-derived growth factor receptor $\beta$ activation and regulation in murine myelofibrosis. <i>Haematologica</i> , 2020, 105, 2083-2094.	1.7	20
28	ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma. <i>Cancer Letters</i> , 2020, 489, 121-132.	3.2	8
29	Quantitative, qualitative and spatial analysis of lymphocyte infiltration in periapillary and pancreatic adenocarcinoma. <i>International Journal of Cancer</i> , 2020, 146, 3461-3473.	2.3	39
30	An immune gene expression signature distinguishes central nervous system metastases from primary tumours in nonâ€“small-cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 24-34.	1.3	14
31	PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. <i>PLoS ONE</i> , 2020, 15, e0243900.	1.1	11
32	Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung. <i>BMC Cancer</i> , 2019, 19, 741.	1.1	10
33	A clonal expression biomarker associates with lung cancer mortality. <i>Nature Medicine</i> , 2019, 25, 1540-1548.	15.2	75
34	Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 628-640.	0.5	54
35	LIPGâ€“promoted lipid storage mediates adaptation to oxidative stress in breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 901-915.	2.3	41
36	NKâ€“and Tâ€“cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of antiâ€“CTLAâ€“4 therapy. <i>International Journal of Cancer</i> , 2019, 145, 2238-2248.	2.3	31

#	ARTICLE	IF	CITATIONS
37	c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 133, 69-74.	0.9	22
38	Cancer stemness, intratumoral heterogeneity, and immune response across cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9020-9029.	3.3	372
39	A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 5207.	1.6	17
40	Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray. <i>Clinical Lung Cancer</i> , 2019, 20, 258-262.e1.	1.1	23
41	Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer. <i>Scientific Reports</i> , 2019, 9, 1319.	1.6	11
42	Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. <i>Lung Cancer</i> , 2019, 130, 50-58.	0.9	127
43	Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases. <i>Human Pathology</i> , 2019, 84, 221-230.	1.1	39
44	Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2018, 143, 1741-1752.	2.3	65
45	Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1092-1098.	2.8	48
46	Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. <i>Journal of Pathology</i> , 2018, 244, 421-431.	2.1	159
47	COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer. <i>Acta Oncologica</i> , 2018, 57, 244-250.	0.8	20
48	The Role of TGF- $\beta$ 2 Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3611.	1.8	66
49	Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases. <i>American Journal of Clinical Pathology</i> , 2018, 150, 533-544.	0.4	27
50	LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease. <i>Lung Cancer</i> , 2018, 125, 174-184.	0.9	17
51	An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1676-1691.	0.5	21
52	Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 125, 157-163.	0.9	16
53	An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer. <i>Journal of Pathology</i> , 2018, 246, 154-165.	2.1	17
54	Antitumoral effect and reduced systemic toxicity in mice after intra-tumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 114, 186-193.	2.0	11

#	ARTICLE	IF	CITATIONS
55	Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. <i>Cancer Research</i> , 2017, 77, 1730-1740.	0.4	29
56	Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters. <i>Modern Pathology</i> , 2017, 30, 964-977.	2.9	17
57	Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1257-1267.	0.5	43
58	Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity. <i>Nature Biomedical Engineering</i> , 2017, 1, 796-806.	11.6	131
59	The clinical impact of tumour-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study. <i>International Journal of Cancer</i> , 2017, 141, 1654-1666.	2.3	65
60	A pathology atlas of the human cancer transcriptome. <i>Science</i> , 2017, 357, .	6.0	2,570
61	RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer. <i>Genes and Development</i> , 2017, 31, 2099-2112.	2.7	32
62	Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC. <i>Molecular Cancer Research</i> , 2017, 15, 1354-1365.	1.5	25
63	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. <i>Modern Pathology</i> , 2017, 30, 1411-1421.	2.9	151
64	PD-L1 immunohistochemistry in clinical diagnostics: Inter-pathologist variability is as high as assay variability.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20637-e20637.	0.8	1
65	Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. <i>PLoS ONE</i> , 2017, 12, e0187246.	1.1	51
66	The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 72108-72126.	0.8	53
67	Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 848-859.	0.6	64
68	Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 648-659.	0.6	26
69	Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. <i>International Journal of Cancer</i> , 2016, 139, 1129-1139.	2.3	192
70	Fibroblast VEGF receptor 1 expression as molecular target in periodontitis. <i>Journal of Clinical Periodontology</i> , 2016, 43, 128-137.	2.3	16
71	Transcriptome analysis of periodontitis-associated fibroblasts by CAGE sequencing identified DLX5 and RUNX2 long variant as novel regulators involved in periodontitis. <i>Scientific Reports</i> , 2016, 6, 33666.	1.6	18
72	Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 603.	1.1	33

#	ARTICLE	IF	CITATIONS
73	Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2016, 9, 21.	1.3	76
74	The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. <i>Journal of Thoracic Oncology</i> , 2016, 11, 862-872.	0.5	70
75	Profiling cancer testis antigens in non-small-cell lung cancer. <i>JCI Insight</i> , 2016, 1, e86837.	2.3	82
76	Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy. <i>PLoS ONE</i> , 2016, 11, e0167585.	1.1	44
77	The protein kinase LKB1 negatively regulates bone morphogenetic protein receptor signaling. <i>Oncotarget</i> , 2016, 7, 1120-1143.	0.8	17
78	Prognostic impact of tumor-associated B-cells and plasma cells in esophageal and gastric adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 63-63.	0.8	0
79	Identification of sample annotation errors in gene expression datasets. <i>Archives of Toxicology</i> , 2015, 89, 2265-2272.	1.9	46
80	Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. <i>BMC Cancer</i> , 2015, 15, 125.	1.1	35
81	LRIG1 is a prognostic biomarker in non-small cell lung cancer. <i>Acta Oncologica</i> , 2015, 54, 1113-1119.	0.8	27
82	HaloPlex Targeted Resequencing for Mutation Detection in Clinical Formalin-Fixed, Paraffin-Embedded Tumor Samples. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 729-739.	1.2	16
83	Prognostic impact of COX-2 in non-small cell lung cancer: A comprehensive compartment-specific evaluation of tumor and stromal cell expression. <i>Cancer Letters</i> , 2015, 356, 837-845.	3.2	28
84	Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome. <i>Anticancer Research</i> , 2015, 35, 3979-85.	0.5	23
85	Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2014, 135, 2206-2214.	2.3	82
86	Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History. <i>Clinical Cancer Research</i> , 2014, 20, 4912-4924.	3.2	24
87	Prognostic relevance of cancer-associated fibroblasts in human cancer. <i>Seminars in Cancer Biology</i> , 2014, 25, 61-68.	4.3	215
88	An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4660-4672.	3.2	81
89	The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. <i>Cancer Letters</i> , 2013, 333, 222-228.	3.2	162
90	Biomarker Discovery in Non-Small Cell Lung Cancer: Integrating Gene Expression Profiling, Meta-analysis, and Tissue Microarray Validation. <i>Clinical Cancer Research</i> , 2013, 19, 194-204.	3.2	293

#	ARTICLE	IF	CITATIONS
91	Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. <i>International Journal of Cancer</i> , 2013, 132, 2020-2031.	2.3	32
92	In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics. <i>Oncotarget</i> , 2013, 4, 2407-2418.	0.8	42
93	Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status. <i>PLoS ONE</i> , 2013, 8, e78614.	1.1	23
94	A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin $\hat{p}$ C as a Compatible Prognostic Marker in Human Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 2695-2703.	3.2	237
95	Consistent mutation status within histologically heterogeneous lung cancer lesions. <i>Histopathology</i> , 2012, 61, 744-748.	1.6	17
96	CD99 is a novel prognostic stromal marker in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2012, 131, 2264-2273.	2.3	63
97	Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. <i>Genome Biology</i> , 2011, 12, R108.	13.9	79
98	Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1833-1840.	0.5	50
99	Forkhead Box F1 Regulates Tumor-Promoting Properties of Cancer-Associated Fibroblasts in Lung Cancer. <i>Cancer Research</i> , 2010, 70, 2644-2654.	0.4	84
100	Impact of Thawing on RNA Integrity and Gene Expression Analysis in Fresh Frozen Tissue. <i>Diagnostic Molecular Pathology</i> , 2009, 18, 44-52.	2.1	83
101	A novel strategy based on histological protein profiling <i>in silico</i> for identifying potential biomarkers in urinary bladder cancer. <i>BJU International</i> , 2009, 104, 1780-1785.	1.3	14
102	Regulation of tyrosine phosphatases in the adventitia during vascular remodelling. <i>Biochemical and Biophysical Research Communications</i> , 2009, 382, 678-684.	1.0	6
103	Quantification of Normal Cell Fraction and Copy Number Neutral LOH in Clinical Lung Cancer Samples Using SNP Array Data. <i>PLoS ONE</i> , 2009, 4, e6057.	1.1	21
104	In Situ Identification of Genes Regulated Specifically in Fibroblasts of Human Basal Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1516-1523.	0.3	55
105	Biobanking of fresh frozen tissue: RNA is stable in nonfixed surgical specimens. <i>Laboratory Investigation</i> , 2006, 86, 202-211.	1.7	196
106	Laser-Assisted Cell Microdissection Using the PALM System. , 2005, 293, 151-166.		46
107	Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 1217-1233.	1.5	137
108	Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. <i>Lung Cancer</i> , 2004, 45, S163-S175.	0.9	297